Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases
Open Access
Abstract
BACKGROUND: In the past 3 decades, a better understanding of gene mutations and their role in carcinogenesis has led to improvement in our ability to treat patients with metastatic disease. The objective of the current study was to determine whether the location of a driver mutation within an affected gene impacts the biology of metastatic colorectal cancer.METHODS: DNA was collected from 165 randomly selected specimens of patients who underwent margin‐negative resection of colorectal liver metastases with curative intent. Sequenom analysis and Sanger sequencing were used to evaluate mutations in K/NRAS, PIK3CA, BRAF, and TP53.RESULTS: BRAF mutation was associated with early recurrence and death, whereas no impact of TP53 or PIK3CA mutation was identified. Although K/NRAS mutation was associated with worse survival in this cohort, this difference was no longer evident when those who had received anti‐EGFR therapy were excluded. When stratifying patients according to the exon on which K/NRAS was mutated, there were dramatic differences in both survival and pathologic features. Exon 4 mutations were associated with large, solitary metastases occurring at long disease‐free intervals compared with exon 3 mutations, which presented with small, numerous lesions. Patients who had exon 4 mutations recurred infrequently and had significantly longer survival compared with those who had wild type or other mutations.CONCLUSIONS: By using this model of curative‐intent, margin‐negative resection in patients at high risk of recurrence, the authors were able to establish a link between mutation location within the K/NRAS gene and the biology of metastatic colorectal cancer. Cancer 2017;123:568–575. © 2016 American Cancer Society.Keywords
This publication has 24 references indexed in Scilit:
- RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver MetastasesAnnals of Surgery, 2013
- Treatment of Metastatic Colon Cancer: “The Times They Are A-Changing”Journal of Clinical Oncology, 2013
- Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human CancerCancer Research, 2010
- The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patientsAnnals of Oncology, 2010
- High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practiceAnnals of Oncology, 2010
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine TherapyClinical Cancer Research, 2008
- Hepatic Resection for Colorectal MetastasesAnnals of Surgery, 2007
- High Frequency of Mutations of the PIK3CA Gene in Human CancersScience, 2004
- A genetic model for colorectal tumorigenesisCell, 1990